UPDATE: Wedbush Securities Initiates Regulus Therapeutics at Outperform on Pipeline Progress

Wedbush Securities initiated coverage on Regulus Therapeutics

with an Outperform rating and a $10 price target. Wedbush Securities noted, "Regulus is developing oligonucleotide drugs that target microRNA, important regulators of gene expression whose dysregulation is implicated in a variety of diseases and disease states. Oligonucleotide drug discovery and development is rapid and predictable as drugs are assembled using the complementary microRNA target as a template, and other oligonucleotide drugs inform ADME, pK, safety and tolerability." Regulus Therapeutics closed at $4.34 on Wednesday.